Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.34 |
| ▸ | HTR2A | P28223 | 5/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 2/20 | 0.32 |
| ▸ | GNRHR | P30968 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.31 |
| ▸ | MEN1 | O00255 | 3/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | APAF1 | O14727 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL905938 | 0.85 | HTR2C (0.36) | HTR2CHTR2ABACE1ALDH1A1MEN1 | |
| SCHEMBL7471371 | 0.83 | HTR2A (0.46) | HTR2CHTR2ABACE1ALDH1A1MEN1 | |
| SCHEMBL905955 | 0.83 | HTR2A (0.46) | HTR2CHTR2ABACE1ALDH1A1MEN1 | |
| Ammonia Solution, Strong SCHEMBL905923 | 0.81 | RAB9A (0.40) | HTR6ALDH1A1MEN1KMT2AMAPT | |
| Fumaric Acid SCHEMBL6626918 | 0.77 | NPSR1 (0.38) | HTR2CHTR2ABACE1ALDH1A1MEN1 | |
| Fumaric Acid SCHEMBL6626910 | 0.77 | NPSR1 (0.38) | HTR2CHTR2ABACE1ALDH1A1MEN1 | |
| SCHEMBL905786 | 0.76 | HTR6 (0.38) | HTR2CHTR6BACE1ALDH1A1MEN1 | |
| SCHEMBL7529719 | 0.76 | HTR6 (0.38) | HTR2CHTR6BACE1ALDH1A1MEN1 | |
| SCHEMBL905921 | 0.76 | — | — | |
| SCHEMBL6628060 | 0.76 | HTR6 (0.38) | HTR2CHTR6BACE1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1202965-B1 | INDOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR MEDICINAL APPLICATION | VERNALIS RES LTD (GB) | 2004-10-13 | — | — | EP | claimed |
| US-6706750-B1 | USEFUL IN TREATING OBESITY AND OTHER DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2004-03-16 | — | — | US | claimed |
| US-20110152272-A1 | Treatment Of Incontinence | PFIZER INC | 2011-06-23 | — | — | US | disclosed |
| EP-2277513-A2 | Treatment of incontinence with 5htc2 agonists | Pfizer Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20080146583-A1 | Treatment of Incontinence | PFIZER INC | 2008-06-19 | — | — | US | disclosed |
| EP-1620081-A2 | TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS | Pfizer Limited (GB) | 2006-02-01 | — | — | EP | disclosed |
| US-20040235856-A1 | Treatment of incontinence | PFIZER INC | 2004-11-25 | — | — | US | disclosed |
| WO-2004096196-A2 | TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS | PFIZER LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
| EP-1202965-B1 | INDOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR MEDICINAL APPLICATION | VERNALIS RES LTD (GB) | 2004-10-13 | — | — | EP | disclosed |
| US-6706750-B1 | USEFUL IN TREATING OBESITY AND OTHER DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2004-03-16 | — | — | US | disclosed |
| EP-1202965-A1 | INDOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR MEDICINAL APPLICATION | VERNALIS RESEARCH LIMITED (GB) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001012603-A1 | INDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR MEDICINAL APPLICATION | VERNALIS RESEARCH LIMITED (GB) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235856-A1 | Treatment of incontinence | HTR2C, HTR5A, ADRA2C | HTR2C 1/4885HTR2A 6/4885HTR6 21/4885 |
| US-20110152272-A1 | Treatment Of Incontinence | HTR2C, HTR5A, ADRA2C | HTR2C 1/4885HTR2A 6/4885HTR6 21/4885 |
| US-20080146583-A1 | Treatment of Incontinence | HTR2C, HTR5A, ADRA2C | HTR2C 1/4885HTR2A 6/4885HTR6 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.